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Abstract
Transcription of the ascorbate transporter, SVCT2, is driven by two distinct promoters in exon 1 of the transporter sequence.
The exon 1a promoter lacks a classical transcription start site and little is known about regulation of promoter activity in the
transcription start site core (TSSC) region. Here we present evidence that the TSSC binds the multifunctional initiator-
binding protein YY1. Electrophoresis shift assays using YY1 antibody showed that YY1 is present as one of two major
complexes that specifically bind to the TSSC. The other complex contains the transcription factor NF-Y. Mutations in the
TSSC that decreased YY1 binding also impaired the exon 1a promoter activity despite the presence of an upstream
activating NF-Y/USF complex, suggesting that YY1 is involved in the regulation of the exon 1a transcription. Furthermore,
YY1 interaction with NF-Y and/or USF synergistically enhanced the exon 1a promoter activity in transient transfections and
co-activator p300 enhanced their synergistic activation. We propose that the TSSC plays a vital role in the exon 1a
transcription and that this function is partially carried out by the transcription factor YY1. Moreover, co-activator p300 might
be able to synergistically enhance the TSSC function via a ‘‘bridge’’ mechanism with upstream sequences.
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Introduction
Since most mammalian cells and all human cells are unable to
synthesize vitamin C, or ascorbic acid, they are dependent upon
uptake of the vitamin from their surroundings. This uptake is
mediated primarily by one of two sodium-and energy-dependent
vitamin C transporters, termed SVCT1(slc23a1) and SVCT2
(slc23a2) [1]. The SVCT1 is located primarily in intestinal
epithelium and renal proximal tubule cells, where it mediates
ascorbate absorption and reabsorption, respectively. The SVCT2,
on the other hand, has a more generalized tissue distribution in
most major organs, with highest expression noted in brain and
neuroendocrine tissues, such as pituitary and adrenal gland.
The SVCT2 is crucial for ascorbate uptake in metabolically
active and specialized tissues. Although SVCT2-deficient embryos
typically survive until birth, they die shortly thereafter, failing to
take a first breath and inflate the lungs [2]. The cause of death
seems to relate to damage in the brain due to capillary
hemorrhage. This is most evident in the cortex, but also occurs
in areas of the lower brain crucial for control of body functions,
including respiration [3].
In nucleated cells a variety of agents enhance SVCT2
expression at the levels of mRNA, protein, and function. In some
instances this accompanies cell differentiation, such as with zinc
[4], calcium/phosphate ions [5] and phorbol ester [6]. In others it
is not related to cell differentiation, such as when induced by
glucocorticoids [7], epidermal growth factor [8], or hydrogen
peroxide [9]. Whereas these results show transcriptional regulation
of the SVCT2, they do not define the molecular mechanism by
which this occurs.
Concerning human SVCT2 regulatory regions, Rubin and co-
workers identified two distinct promoters (CpG-poor exon 1a
promoter and CpG-rich exon 1b promoter) located immediately
upstream of the first two exons (termed exon 1a and exon 1b) [10].
The SVCT2 exon 1b is ubiquitously expressed in human and
mouse tissues. Although this promoter doesn’t contain a classical
TATA box, it contains a functional initiator that binds Yin Yang-1
(YY1) and interacts with upstream Sp1/Sp3 elements in the
proximal promoter region [10,11]. These elements play a critical
role in regulating YY1-mediated transcription of the exon 1b.
Formation of YY1/Sp complexes on this promoter is required for
its optimal function. Additionally, both EGR-1 and -2 were also
detected in the protein complexes that bound the three GC boxes
bearing overlapping binding sites for EGR/WT1 and Sp1/3. The
EGR family factors, WT1 and MAZ were found to differentially
regulate the exon 1b promoter activity [11].
In contrast to the ubiquitously expressed SVCT2 exon 1b, the
expression of the SVCT2 exon 1a exhibits cell-specificity, found in
some cell types and not in others [12]. Exon 1a is regulated by the
interaction of the transcription factors Upstream Stimulating
Factor (USF) and Nuclear Factor-Y (NF-Y), in that USF1/2 and
NF-Y bind to the upstream sequence of the exon 1a promoter in a
cooperativity-dependent manner and form an activating complex
[12]. The formation of this NF-Y/USF complex is absolutely
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bisulfite genomic sequencing revealed that CpG methylation at the
upstream USF-binding site predicted the observed cell-specific
expression of this promoter. Specific methylation of this CpG site
impaired both USF binding and the formation of the functional
NF-Y/USF activating complex with a resulting decrease in
promoter activity. Although these studies describe one mechanism
of upstream regulation of the exon 1a promoter, it is also likely
that activity of this promoter also depends on transcription factors
binding on or near the transcription start site.
Due to the presence of ubiquitous transcription factors, the exon
1a 59 region could be protected against remethylation in transient
transfection and the exon 1a promoter clearly exhibited similar
transcriptional activity in both exon 1a-expressing cells and non-
expressing cells [12]. Thus, we employed both exon 1a-expressing
cells (EA.hy926) and non-expressing cells (HeLa) further to
characterize the sequences that comprise the transcription start
site core (TSSC) of the SVCT2 exon 1a, which is positioned
downstream of the E/Y boxes and overlaps the transcription
initiation site. We determined that two protein-DNA complexes,
TSSC(A) and TSSC(B), bind specifically to the TSSC region and
identified TSSC(A) and TSSC(B) as YY1 and NF-Y, respectively.
We also found that the YY1 protein and its binding site are
necessary for the full promoter activity and that YY1 activates
transcription from the exon 1a promoter. Additionally, the non-
DNA-binding transcriptional co-activator p300 is also involved in
the transcriptional regulation of the SVCT2 exon 1a, very likely
via a ‘‘bridge’’ mechanism.
Results
The TSSC of the exon 1a promoter contains two adjacent
YY1 binding sites and binds two protein complexes
To evaluate the role of the TSSC downstream of functional NF-
Y/USF elements in the regulation of the exon 1a promoter, we
used gel-shift assays to detect additional transcription factors
binding to this DNA region. We observed two major protein-DNA
complexes, designated TSSC(A), and TSSC(B), binding to this
element (Fig. 1A and B). Inspection of the TSSC sequence
identified two potential binding sites for the multifunctional
transcription factor YY1 [13]. YY1 has been shown to bind to
sequences overlapping transcription start sites, where it functions
to activate transcription [14,15,16]. As shown in Fig. 2A, the
TSSC contains two copies of the core sequence 59-CAT-39 that
individually are necessary for YY1 binding [16,17]. Based on the
sequence similarity between the TSSC and YY1 binding sites, we
explored the possibility that YY1 is a component of these
complexes. As shown in Fig. 1A, the TSSC(A) complex was
shifted to a position co-migrating with the TSSC(B) complex upon
addition of YY1 antibody, but unaffected by addition of antibody
directed against USF1 or by the preimmune serum. The upper
complex, TSSC(B), was not affected. The canonical YY1
oligonucleotide derived from the SVCT2 exon 1b promoter
served as a positive control. These data confirm that TSSC(A)
complex contains YY1 protein. Similar results were observed in
both human derived cell lines, HeLa and EA.hy926.
The TSSC of the exon 1a promoter contains an almost perfect
match (7 out of 8 residues) to the TFII-I motif of 59-YAYTCYYY-
39 (where Y is a pyrimidine residue) (Fig. 2A) [18]. However,
excess of a known TFII-I binding sequence from the serum
response element (SRE) did not disturb the TSSC(B) complex
(Fig. 1B). TFII-I antibody also failed to affect the TSSC(B) band,
nor did it produce a super-shifted band. This suggests that TFII-I
does not bind to the TSSC(B).
Rigby and his colleagues have previously shown that NF-Y is
able to bind both the HoxTF/YY1 site (TGGCCATT) [19] and
the b4Cwt site (TCGCCATT) [20] in the Hoxb4 promoter. As
shown in Fig. 1B, a 29-bp competitor oligonucleotide containing a
canonical CCAAT binding site (Y box) derived from the SVCT2
exon 1a promoter [12] competed efficiently for TSSC(B) binding
without affecting YY1 binding, whereas the nonspecific competitor
(XDH/XO), exon 1a promoter-derived E box [12] and the
mutated Y box failed to compete. Finally, the retarded band
observed with the TSSC was completely super-shifted with the
anti-NF-YA antibody, verifying that the NF-Y trimer has TSSC(B)
binding activity (Fig. 1B). Again, comparable results were observed
for both HeLa and EA.hy926 cells.
The 39YY1 binding site exclusively binds YY1, whereas
the 59YY1 binding site binds both NF-Y and YY1
We have demonstrated that the TSSC(A) and TSSC(B) DNA-
protein complexes contain YY1 and NF-Y, respectively. The
TSSC element contains two overlapping sequences with homology
to the YY1 consensus binding site (Fig. 2A). Both the 59 and
39YY1 sites are identical to the invariant core sequence (59-CAT-
39) of the YY1 consensus motif [17]. To determine the site binding
specificity of YY1/NF-Y within the TSSC element, oligonucleo-
tides containing specific mutations of the core consensus sequence
in either the 59YY1 site (m59YY1GC, m59YY1G2, m59YY1G3,
m59YY1TTG, and m59YY1C4), the 39YY1 site (m39YY1 and
m39YY1G7), or both sites (m5939YY1 and mYY1G3,7) of the
TSSC element of the exon 1a promoter were engineered (Fig. 2B
and Table 1).
We tested the capacity of these oligonucleotides to compete for
the binding of nuclear YY1 and NF-Y to the wild-type TSSC
sequence. As shown in Fig. 2C, addition of excessive wild-type
sequence completely abolished both complexes (lane 3), whereas
the double mutant m5939YY1 was unable to disrupt either YY1 or
NF-Y (lane 4). The competitors m59YY1TTG and m59YY1GC
also failed to compete effectively for NF-Y binding (lanes 6, 7, 10
and 14) suggesting that NF-Y specifically recognizes the 59YY1
binding site within the TSSC element. However, the
m59YY1TTG mutant partially competed for YY1 binding,
indicating that the TTG mutation not only eliminated NF-Y
binding, but also reduced YY1 activity. Javahery et al has
demonstrated that a change of the YY1 core consensus from
CCAT to ttgT completely eliminates YY1 binding and appears
not to affect the 39YY1 binding site [16]. This indicates that part
of YY1 binding activity appears to derive from the 59YY1 site.
Consistent with this observation, the mutation of the 39YY1 site
(m39YY1) disrupted most of YY1 binding and abolished NF-Y
binding (lane 12). The m59YY1GC and m59YY1C4 mutant
sequences completely abolished YY1 binding, probably because of
the production of a high affinity binding site (CCATCTT) for YY1
(lanes 7, 13 and 14). Moreover, in contrast to the positive control
(Fig. 2D, lane 10), the competitors bearing a critical nucleotide
mutation for YY1 binding sites (m59YY1G3 and m39YY1G7)
(Fig. 2D, lane 10) [11,16,21] still completely eliminated YY1 and
NF-Y complexes (Fig. 2C, lanes 5, 9 and 11). This further suggests
that either the 59 or the 39YY1 binding site is capable of binding
YY1. These results provide evidence that NF-Y specifically
recognizes the 59YY1 binding site within the TSSC element and
that YY1 is capable of binding either the 59YY1 or the 39YY1 site.
To directly test the ability of nuclear extracts containing YY1/
NF-Y to bind the 59/39YY1 sites, EMSA was performed with the
labeled mutant oligonucleotides described above. The results of
these experiments are shown in Fig. 2D. Mutation of both YY1
sites eliminated the TSSC binding (lane 2). The oligonucleotide
SVCT2 Exon 1a Promoter Regulation
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binding activity, but did not affect NF-Y binding activity (lane 3).
Several mutations in the 59YY1 site were also tested. A single point
mutation of the 59YY1 site at +2 from A to G (m59YY1G2)
abolished NF-Y binding activity without affecting the binding of
YY1 (lanes 6 and 13), and another point mutation at +4 from T to
C (m59YY1C4) severely impaired NF-Y binding activity and
improved YY1 binding (lane 7), indicating that the 39YY1 site
contributes to YY1 binding since +4 mutation does not impair 59
YY1 binding (lane 11) [11]. The combined mutation (m59YY1GC)
completely eliminated NF-Y binding activity and produced a high
affinity binding site for YY1 (lane 5). The mutant m59YY1TTG
still retained weak binding for YY1 (lane 4). In addition, the
mutant bearing a critical nucleotide mutation in each of YY1
binding sites (mYY1G3,7) completely abolished YY1 binding and
increased NF-Y binding (lanes 8 and 14). Taken together, the
observations from Fig. 2 strongly support the notion that NF-Y
specifically recognizes the 59YY1 binding site and YY1 is capable
of recognizing either the 59YY1 or the 39YY1 binding site.
YY1-mediated transcriptional activation of the exon 1a
promoter requires the integrity of two adjacent YY1 sites
to maintain the optimal promoter activity
To further evaluate the role of the two YY1 sites and YY1/NF-
Y transcription factors in the regulation of the exon 1a promoter
activity, we tested the capacity of the exon 1a reporter constructs
carrying the various mutations in both YY1 binding sites (as
depicted in Fig. 2B and Table 1) to affect the exon 1a promoter
activity. As shown in Fig. 3, the mutants m59YY1TTG and
m5939YY1 both decreased the promoter activity by about 50–
70%, consistent with the patterns of impaired YY1/NF-Y binding.
Improved NF-Y binding maintained exon 1a promoter activity in
Figure 1. YY1 and NF-Y bind to the TSSC element of the exon 1a promoter. (A) and (B) HeLa or EA.hy926 cell nuclear extract (NE) was
incubated with a labeled probe containing the TSSC of the exon 1a promoter and the reaction mixture was electrophoresed on a 4.5% non-
denaturing gel to detect the specifically retarded migrating band. The indicated unlabeled probes or antibodies were added prior to labeled probes
for competition or super-shift analysis. The canonical YY1 oligonucleotide derived from the SVCT2 exon 1b promoter served as a positive control. A
super-shifted complex is indicated by an *. Note: TSSC(A9), unidentified binding complex.
doi:10.1371/journal.pone.0035746.g001
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m39YY1G7 and mYY1G3,7), and vice versa (m59YY1GC and
m59YY1C4). In contrast, m39YY1, which impairs the binding of
YY1, but does not significantly affect NF-Y binding, significantly
decreased exon 1a promoter activity. The mutant (m59YY1G2)
that impairs NF-Y binding without affecting YY1 binding slightly
decreased promoter activity. These data suggest that both YY1
sites within the TSSC element are required to maintain the
maximal promoter activity and that positive regulation is mediated
through the binding of YY1 and NF-Y.
To directly confirm that YY1 exerts a positive effect on the exon
1a promoter, we tested whether transfection of YY1 could trans-
activate the exon 1a promoter. As shown in Fig. 4A, a significant
response was observed with maximal stimulation of YY1
expression resulting in a 5–6-fold activation. As an additional
control, the low level of expression observed with the empty
reporter vector was not altered by YY1. To further demonstrate
the involvement of YY1 in the exon 1a promoter activation, a
dominant-negative YY1 mutant (YY1S339/S342) was employed
to interfere with binding of the endogenous YY1 to the exon 1a
promoter. This mutant lacks the ability to bind specific YY1-target
sequences, but retains the capability of wild type protein for
protein–protein interactions [22]. As shown in Fig. 4B, basal
transcription was substantially inhibited by ectopically expressed
YY1S339/S342. These data further confirm that YY1 plays a
positive regulatory role in the transcription of the exon 1a
promoter.
To elucidate the role of NF-Y in YY1-mediated trans-activation
of the exon 1a promoter, reporter gene expression was evaluated
in transient transfection assays using YY1 construct and exon 1a
promoter mutants with mutations as described in Fig. 2B and
Table 1. As observed in Fig. 4A, Fig. 4C shows that the wild type
exon 1a promoter (2106/+266) was up-regulated 4.6-fold in
response to the exogenous expression of YY1. When the YY1
binding sites were mutated and YY1/NF-Y binding was
completely eliminated (m5939YY1), YY1 still stimulated exon 1a
Figure 2. Characterization of the TSSC element of the exon 1a promoter. (A) The consensus sequence for YY1 binding is shown, where the
upper case letters represent the preferred bases. The YY1 binding site contains a conserved core 59-CAT-39, which is essential for efficient binding,
and is flanked on either side by variable regions. Two potential binding sites for YY1 were identified within the TSSC element and each putative
binding site for YY1 is marked. (C) Competition gel shift assays were performed with HeLa nuclear extract to define the binding specificity of YY1 and
NF-Y to the TSSC element. Each competitor used was added in a 200-fold molar excess. The applied competitors with mutations in the YY1 consensus
site are described in (B) and Table 1.( D) Ability of the TSSC mutant oligonucleotides to form YY1 or NF-Y complexes. Wild type TSSC and 59 and/or
39YY1 mutant oligonucleotides were labeled and used in EMSAs with HeLa nuclear extract. Note: TSSC(A9), unidentified binding complex.
doi:10.1371/journal.pone.0035746.g002
SVCT2 Exon 1a Promoter Regulation
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35746promoter activity by two-fold, although YY1 activation was
attenuated nearly 4-fold compared with the wild type control
construct (Fig. 4C). When YY1 binding was severely impaired with
increased NF-Y binding (m59YY1G3, m39YY1G7 and
mYY1G3,7), or NF-Y binding was nearly eliminated with
increased YY1 binding (m59YY1C4), YY1 activation of the exon
1a promoter was slightly decreased. Promoter activation occurred
even when YY1 binding was completely eliminated (mYY1G3,7).
These results suggest that TSSC-bound NF-Y may contribute to
YY1-mediated induction of the exon 1a promoter. The
m59YY1TTG or m39YY1 mutants resulted in only two-fold
YY1 activation (less than 40% of wild type). These results suggest
that YY1-mediated trans-activation of the exon 1a promoter
requires the integrity of the NF-Y binding site as well as the YY1
binding sites within TSSC element. Our finding that YY1 was still
able to activate the exon 1a promoter despite of the absence of the
YY1 binding site raises the possibility that YY1 might interact with
other factors directly or indirectly bound to the exon 1a promoter
in the absence of YY1 binding site. Owing to the key role of the
upstream Y box and its bound NF-Y, we are unable to definitively
assign any function to TSSC-bound NF-Y, although our results
suggest a positive regulation on the exon 1a promoter activity.
YY1 synergistically activate the exon 1a promoter along
with NF-Y and USF
In our previous study, we showed that NF-Y bound to the Y box
interacts with USF1/2 bound to the E box on the upstream
promoter, and that the formation of the NF-Y/USF complex is
absolutely required for the full activity of the exon 1a promoter
[12]. To further investigate the functional relationship between
YY1, NF-Y and USF in regulating the exon 1a promoter activity,
YY1, NF-Y and USF constructs were co-transfected with the exon
1a promoter into HeLa cells. As shown in Fig. 5A, transfection
with either YY1 or NF-Y alone increased promoter activity by
two-fold. On the other hand, co-transfection of YY1 with NF-Y
synergistically increased promoter activity to 8-fold. The 59YY1
site mutation (m59YY1TTG), which impairs YY1 binding and
completely abolishes NF-Y binding, still produced a synergistic
response to the combination of NF-Y and YY1. This suggests that
the Y box located in the 274/270 region and its bound NF-Y
play a critical role in the YY1-induced response. In contrast, the
mutation of this Y box (2106/+266YD) [12] abrogated any
response to YY1 and/or NF-Y (Fig. 5A).
As with NF-Y, co-transfection of YY1 with USF1/2 also
synergistically increased the promoter activity to 16-fold over that
of the intact promoter alone (Fig. 5B). This was a level that was
twice that of USF1/2 alone. However, NF-Y failed to synergis-
tically enhance USF1/2-mediated activation, although NF-Y and
USF bind to the exon 1a promoter in a cooperativity-dependent
manner [12]. On the other hand, the combination of YY1, NF-Y
and USF1/2 dramatically enhanced the promoter activity to 21-
fold compared to the 2106/+266 construct alone. These
observations show that NF-Y, USF and YY1 synergistically
activate the exon 1a promoter activity compared to each factor
alone.
p300 synergistically regulates the exon 1a promoter
activity via the interaction with other transcription
factors
The preceding results show that YY1-mediated induction of the
exon 1a promoter is dependent on the integrity of NF-Y/USF
binding sites upstream of the TSSC element and that YY1 and
Table 1. Probes used in the current study.
Name Sequence
YY1 5-CTCCGCGGCGCCATTTTGCAGGCGGCT-3
TSSC 5- GAGCAGGGCCATTCATCTTCTCCTGCCC-3
XDH/XO 5-CCGGGAGGCGTATCTTTCAAGTTGCAGGGCAGT-3
SRE 5- AATTCTCCTTTACACAGGATGTCCATATTAGGACATCTC-3
E box 5-TCCACTTTCACCCACGTGAGCAGGCATCAT-3
Y box 5-AGCAGGCATCATCCAATCCACTGTGGGTC-3
mY box 5-AGCAGGCATCATCCAGGCCACTGTGGGTC-3
YY1m+3 5-CTCCGCGGCGCCAGTTTGCAGGCGGCT-3
YY1m+4 5-CTCCGCGGCGCCATCTTGCAGGCGGCT-3
m5939YY1 5-GAGCAGGGCCAGGGGGGTTCTCCTGCCC-3
m39YY1 5-GAGCAGGGCCATTCAGGGGGGCCTGCCC-3
m59YY1TTG 5-GAGCAGGGTTGTTCATCTTCTCCTGCCC-3
m59YY1GC 5-GAGCAGGGCCGTCCATCTTCTCCTGCCC-3
m59YY1G2 5-GAGCAGGGCCGTTCATCTTCTCCTGCCC-3
m59YY1C4 5-GAGCAGGGCCATCCATCTTCTCCTGCCC-3
m59YY1G3 5-GAGCAGGGCCAGTCATCTTCTCCTGCCC-3
m39YY1G7 5-GAGCAGGGCCATTCAGCTTCTCCTGCCC-3
mYY1G3,7 5-GAGCAGGGCCAGTCAGCTTCTCCTGCCC-3
doi:10.1371/journal.pone.0035746.t001
Figure 3. Effect of 59/39YY1 mutations on the exon 1a promoter transcriptional activity. HeLa and EA.hy926 cells were transfected with
500 ng of TSSC mutants described in Fig. 2B and Table 1. 5 ng of pRL-CMV was added as an internal control for each transfection, and relative
luciferase activity is shown as the means based on the activity of +7/+266. Data represent mean 6 S.E.M. (n=4). *P,0.05 versus 2106/+266.
doi:10.1371/journal.pone.0035746.g003
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Although this could reflect a protein-protein interaction between
YY1 and USF/NF-Y, it does not prove one, since it is possible that
one or more co-activators mediate this effect. It has been shown
that the p300 co-activator can interact with YY1/NF-Y/USF and
facilitate transcriptional activation [23,24,25]. As shown in Fig. 6A,
p300 had no effect on the basal promoter activity when expressed
alone and failed to enhance YY1-mediated promoter activity. On
the other hand, the increase in promoter activity with either NF-Y
or USF alone was further elevated when p300 was also expressed
with each of them (Fig. 6A). That the effect of p300 was specific is
evident from the results shown in Fig. 6B, in which, its closely
related family member CBP had little or no effect on the exon 1a
promoter activity.
Binding of YY1, NF-Y and p300 to the proximal exon 1a
promoter in cells
Chromatin immunoprecipitation (ChIP) assays were used to
directly assess the presence or absence of YY1, NF-Y and p300
bound to the proximal promoter of the endogenous exon 1a gene.
As shown in Fig. 7A, a 119-bp fragment spanning the exon 1a
proximal promoter was detected by PCR in 2% Input. When
DNA from HeLa or EA.hy926 cells was immunoprecipitated with
antibodies to USF1/2, NF-YA, YY1 and p300, the 119-bp region
was detected. As a control for non-specific protein-DNA
interactions, we also amplified a genomic fragment containing a
TFII-I site where no sites for other transcription factors are
detectable by sequence analysis. The resulting 113 bp fragment
from HeLa cells was immunoprecipitated by TFII-I antibody, but
not significantly by antibodies to USF1/2, NF-YA, YY1 or p300
(Fig. 7B). Furthermore, immunoblotting of p300 after immuno-
precipitation with antibodies to YY1, USF2 and NF-YB showed
that the immunoprecipitates contained p300, but neither USF1
nor NF-YA did (Fig. 7C), suggesting that p300 is capable of
mediating the protein-protein interaction among YY1, NF-Y and
USF1/2.
To further demonstrate the relationship between these tran-
scription factors and the SVCT2 exon 1a transcript expression,
EA.hy926 cells were transduced with the lentivirus RNAi
pLKO.1-YY1 or NF-YA vectors to silence YY1 or NF-YA. Four
days after transduction, total protein and mRNA were extracted
from EA.hy926 cells and used to determine YY1/NF-YA protein
levels and SVCT2 exon 1a mRNA level. As shown in Figure 8A
and B, YY1 or NF-YA silencing significantly decreased YY1 or
NF-YA protein levels. Parallel to YY1 or NF-YA silencing, the
exon 1a transcript level was markedly decreased as compared to
those in control cells (Figure 8C and D).
Together, these results provide evidence for the direct
involvement of these transcription factors in the regulation of the
SVCT2 exon 1a expression.
Discussion
Although the critical cis-acting DNA elements (E box and Y
box) required for SVCT2 exon 1a promoter activity have been
determined [12], important core promoter elements have not been
described. Clearly, elucidation of transcriptional regulatory
mechanisms relies on thorough characterization of promoter
sequence. To understand the potent transactivation potential of E
box-bound USF and Y box-bound NF-Y, we have further
characterized the exon 1a promoter to identify possible targets
for regulation within the basal transcriptional machinery. Here we
identified a core region, the TSSC element, which encompasses
the transcription start site and is required for promoter activity. To
identify factors that might regulate the exon 1a expression through
the TSSC element, we inspected the TSSC sequence for
homology to well-characterized initiator-binding proteins. The
TSSC contains two copies of the core sequence 59-CAT-39, which
is predicted to be recognized by the YY1 transcription factor
[17,26,27]. Using immunological techniques, we confirmed that
YY1 is a component of one of the TSSC complexes formed on the
exon 1a promoter. YY1 is a multifunctional transcription factor
that can exert either positive or negative control on a large number
of cellular and viral genes by binding to sites overlapping the
transcription start site. It is ubiquitously expressed and is highly
conserved between mouse and human [13]. YY1 regulates the
expression of a variety of cellular and viral genes such as the
adeno-associated virus P5 promoter (AAV P5) and the cytochrome
oxidase Vb subunit promoter (COX Vb) [14,15,28].
Figure 4. Trans-activation of the exon 1a promoter by YY1. (A)
and (B) HeLa cells were co-transfected with 100 ng of the exon 1a
reporter plasmid (2106/+266-Luc) along with 400 ng of the plasmid
containing YY1 expression plasmid, or 200 ng of promoter constructs
with 300 ng of the dominant-negative mutant YY1S339/S342 as
indicated. (C) Effect of mutation of YY1 binding sites on YY1 induction
of luciferase activity under the control of the exon 1a promoter. 100 ng
of the exon 1a mutants containing mutations as described in Fig. 2B
and Table 1 were transfected into HeLa cells with or without 400 ng of
the YY1 construct. Luciferase activity was measured 24 h after
transfection. Means 6 S.E.M. are shown (n=4). *P,0.01 versus 2106/
+266; **P,0.01 versus 2106/+266 + YY1; #P,0.05; ##P,0.01.
doi:10.1371/journal.pone.0035746.g004
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maintenance of the two intact YY1 binding sites, since specific
mutations within the YY1 core consensus sequence that prohibit
YY1 binding activity also impaired the transcriptional response of
the exon 1a promoter. The YY1 protein positively regulates the
exon 1a promoter, since overexpression of YY1 enhanced
transcriptional activity. We also observed that YY1 is capable of
binding to either of 59/39YY1 binding sites in a functional
manner. However, the two closely adjacent YY1 binding sites
seem highly unlikely to be recognized by two YY1 molecules
simultaneously because of the requirement for flanking residues.
The latter conclusion derives from methylation analysis of the
canonical YY1 sequence derived from SVCT2 exon 1b promoter
(data not shown) and the first intron of Peg3 [29].
We also identified the 59YY1 binding site as an NF-Y/YY1
motif (GCCATT) within the TSSC element of the exon 1a
that includes the two adjacent potential YY1 binding sites
(5-GCCATT
CATCTT-3). The NF-Y/YY1 motif can act as a potential
binding site for NF-Y. Previously, Gilthorpe et al [20] also
described a similar NF-Y/YY1 motif (TCGCCATT) within
Hoxb4 intron C1 region that bound NF-Y and YY1 in mouse
embryo and neuro 2A nuclear extracts. NF-Y binding to the NF-
Figure 5. YY1, NF-Y and USF synergism on the exon 1a promoter. (A) NF-Y synergistically potentiates YY1 induction on the exon 1a
promoter. HeLa cells were transiently transfected with 100 ng of 2106/+266, m59YY1TTG, or 2106/+266YD (the central CCAAT sequence changed to
CCT) reporter constructs in the presence of 200 ng of NF-Y (equimolar mixtures), or/and YY1 constructs. (B) Cells were transiently transfected with
100 ng of 2106/+266 reporter construct in the presence of 300 ng of the expression vectors for NF-Y, USF1/2, or/and YY1. Relative luciferase activity
is shown as the means based on the activity of +7/+266. Means 6 S.E.M. are shown (n=4). *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0035746.g005
Figure 6. Non-DNA-binding transcriptional co-activator p300 is involved in the transcriptional regulation of the exon 1a promoter
and synergistically enhances promoter activity in conjunction with other transcription factors. HeLa cells were transiently transfected
with 100 ng of 2106/+266 reporter constructs in the presence of 600 ng of the expression vectors for p300 (A) or CBP (B) with 300 ng of YY1, NF-Y
(equimolar mixtures) or USF1/2 (equimolar mixtures). The data are shown as means 6 S.E.M. (n=4), with the response level of +7/+266 reporter
construct in the absence of NF-Y, YY1 and p300/CBP set arbitrarily as 1. **P,0.01.
doi:10.1371/journal.pone.0035746.g006
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Hoxb4 in both mesodermal and neural domains and positive
regulation is largely mediated through the binding of NF-Y [20].
However, it seems unlikely that both NF-Y and YY1 can bind
simultaneously because of the requirement for common major
groove interactions [17,20,30]. It would appear, therefore, that the
NF-Y/YY1 site is a specialized motif that is able to bind either
factor in a mutually exclusive fashion.
NF-Y is known to stabilize the binding of other proteins to
regulatory elements close to CCAAT boxes and to interact directly
with other transcription factors. These properties of NF-Y could
be important for the recruitment of additional proteins to the
promoter in order to establish complexes that are capable of
activating transcription. NF-Y can also interact with proteins of
the general transcriptional machinery [31]. In our recent work, the
NF-Y transcription factor was found to increase expression of
SVCT2 exon 1a through its binding to the CCAAT Y box motif
on the exon 1a promoter in cooperation with USF1/2 binding to
the upstream E box [12]. Thus, we speculate that, in cooperation
with upstream DNA-USF/NF-Y complex, NF-Y binding to the
NF-Y/YY1 motif might act to stabilize and enhance the activating
effects of other cell-type specific transcriptional regulators,
maintain this state by the recruitment of chromatin modifying
enzymes, and indirectly stabilize and enhance YY1 binding. This
is also supported by the fact that YY1 still strongly stimulated the
exon 1a promoter activity in the absence of the YY1 binding site.
Although our current analysis supports the possibility that
regulation of the exon 1a expression might be influenced by this
atypical CCAAT box-bound NF-Y and YY1 simultaneously, given
Figure 7. Analysis of transcription factor binding to the exon
1a promoter. (A) ChIP assays were performed using HeLa and
EA.hy926 cells. Antibodies for YY1, NF-Y, USF1/2 and p300 or normal
rabbit IgG were used. Immunoprecipitated DNA fragments and 2% of
total sample DNA were amplified by PCR using primers specific for the
human exon 1a promoter (2106 to +13). PCR products were separated
on a 2% agarose gel and stained by ethidium bromide. (B)
Amplification of an unrelated region showed undetectable signal from
HeLa cell-derived genomic DNA. (C) Co-immunoprecipitation assay
showing the interactions with p300. HeLa cells were lysed and
immunoprecipitated using YY1, USF1, USF2, NF-YA or NF-YB antibodies
followed by immunoblotting with anti-p300 antibody.
doi:10.1371/journal.pone.0035746.g007
Figure 8. Effect of NF-Y and YY1 silencing on the SVCT2 exon
1a expression. (A) and (B) YY1, NF-YA and b-actin protein level of
EA.hy926 cells transduced with pLKO.1-NF-YAi, pLKO.1-YY1i or pLKO.1-
TurboGFPi lentivirus was immunoblotted with specific antibodies. (C)
The SVCT2 exon 1a and b-actin mRNA level of EA.hy926 cells,
transduced as above, was determined by RT-PCR. Data are represen-
tative of three independent experiments. (D) The data is a densito-
metric analysis of 3 independent experiments as means 6 S.E.M. (n=3).
*P,0.05, as compared with control cells.
doi:10.1371/journal.pone.0035746.g008
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NF-Y and YY1 can mediate different transcriptional effects by
reorganizing the local chromatin environment, the relative levels
of NF-Y and YY1 binding could represent a balancing mechanism
for exon 1a activity through the specialized TSSC and this
mechanism might also be involved in the spatially specific
expression of the exon 1a [20].
However, there is lack of evidence demonstrating that YY1 can
directly interact with NF-Y subunits. Here the transcriptional co-
activator p300, but not its closely related family member CBP,
synergistically increased the exon 1a promoter activity via the
interaction with other transcription factors and thus could serve as
a ‘‘bridge’’ for transcription factor interaction. The p300 protein is
a non-DNA-binding transcriptional co-activator that interacts with
transcriptional factors and is implicated in transcriptional
responses to various extracellular and intracellular signals. It
functions by chromatin remodeling and is involved in most cellular
programs, including growth, terminal differentiation, and p53-
mediated apoptosis. Further, p300 is also involved in the activation
of a large number, if not all, the polymerase II-transcribed genes.
Activity of p300 has been studied in a number of systems, with
particular focus on its acetyltransferase enzymatic activity. Three
different functions are attributed to p300. First, the protein serves
as a platform, a bridge, through which the direct interactions with
multiple DNA binding activators are supported; recruitment of
p300 stabilizes and increases the otherwise weak binding of these
factors or even makes them possible [32]. Interactions of p300
with many transcription factors have been mapped in one and
sometimes multiple sub-domains of the co-activator (e.g., NF-Y
binding) [24]. Second, once on a promoter, p300 protein modifies
the chromatin structures nearby the sites by virtue of its histone
acetylation activity, rendering nucleosomes more ‘‘accessible’’ to
the general transcription apparatus. Third, the same histone
acetyltransferase activity increases the affinity of the DNA binding
factor for the targeted sequence and modulates transcriptional
activity. In keeping with this, p300 can acetylate NF-YB and this
modification increases NF-Y-p300 interactions [33]. Considering
the fact that p300 is capable of interacting with YY1, NF-Y and
USF, respectively, the ‘‘bridging’’ mechanism might be predom-
inant for the SVCT2 exon 1a promoter. It is also possible that the
acetylation modification of NF-YB by p300 favors the interactions
of NF-Y-p300-NF-Y and increases the binding of NF-Y to the
canonical Y box and atypical NF-Y/YY1 motif [34,35,36].
Our findings revealed that all of these transcription factors are
bound to their cognate sites on the endogenous SVCT2 exon 1a
promoter in both exon 1a-expressing cells (EA.hy926) and non-
expressing cells (HeLa) and the exon 1a promoter also exhibited
similar transcriptional activity in both types of cell lines [12]. In
this regard, previous studies implied that the total transcription
lack requires a local repression mechanism to prevent activation
by these ubiquitous transcription factors and this local inhibition
appears to depend on the promoter activity [37,38,39]. The
promoter 59 region protection against remethylation is probably
related to the transcriptional activity of the promoter and the
promoter-bound transcription factors. Transcription factors may
either directly prevent access of the DNA methyltransfrase or
indirectly induce histone modifications that exclude these
methylation enzymes against methylation [40,41,42]. Consistent
with this, our current study confirmed that p300 is involved in the
transcriptional regulation of the exon 1a. This co-activator is
capable of interacting with NF-Y/USF functional complex and
synergistically increased the exon 1a promoter activity. The p300
co-activator can function by relaxing the chromatin structure at
the gene promoter through their intrinsic histone acetyltransferase
(HAT) activity. Thus, the exon 1a 59 region could be protected
against remethylation in non-expressing cells due to the presence
of these transcription factors.
These results suggest that these transcription factors might
interact as a complex on the SVCT2 exon 1a promoter via a
‘‘bridging’’ mechanism. Based on it, we propose a simplified
possible model for SVCT2 exon 1a promoter activation by YY1,
NF-Y and USF. Fig. 9 shows how these transcription factors could
converge to form the transcriptional complex required for the
exon 1a gene transcription. First, Y box-bound NF-Y and E box-
bound USF form an activating complex on the upstream of the
exon 1a promoter. Second, the NF-Y/USF protein complex on
the promoter recruits the p300 co-activator. Third, p300 provides
a crucial platform to bind YY1 and NF-Y present in the TSSC
element and also bends the DNA to facilitate the assembly of the
transcriptional complex. Finally, the co-activator p300 may also
interact with other transcription factors or modify histones. The
latter probably represents a critical event for the achievement of an
open chromatin state that could also favor the formation of the
transcriptional complex on the exon 1a promoter.
The experiments reported in this study also demonstrate that
these transcription factors control the cellular expression of
SVCT2 exon 1a and presumably expression of the SVCT2 itself.
Lentivirus-mediated knockdown of NF-YA- or YY1 significantly
impaired exon 1a mRNA expression. Such transcriptional
regulation of SVCT2 expression could well contribute to changes
in SVCT2 protein expression and thus vitamin C uptake. For
example, brain capillary endothelial cells in primary culture do not
express the SVCT2, yet develop begin to express it during the
process of cell culturing and after transient murine stroke [43,44].
In both cases, this may be due to increased oxidative stress.
Further, phorbol ester-induced differentiation of THP-1 mono-
cytes caused a marked increase in both expression and function of
the SVCT2, leading to increases in intracellular ascorbate [6].
Similar increases in ascorbate facilitated THP-1 monocyte
adhesion and morphologic differentiation induced by low
concentrations of PMA, and decreased the expression of the
monocyte-macrophage surface antigen CD14 [6]. Since such
changes in SVCT2 expression may well be due to changes in
SVCT2 transcription, study of the transcriptional regulatory
mechanisms of SVCT2 could provide new insight on how SVCT2
expression might be regulated upon the different stimuli and
environments and contribute to the elucidation of SVCT2’s role
against oxidative stress [6,11,12].
Figure 9. Proposed model for the SVCT2 exon 1a promoter
trans-activation. p300 of the transcriptional complex could act as a
bridging factor among YY1/NF-Y/USF.
doi:10.1371/journal.pone.0035746.g009
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Reagents
The antibodies against USF1 (C-20), USF2 (C-20), YY1 (H-
414), TFII-I (H-58), p300 (NM11), NF-YA (C-18) and NF-YB (C-
20) were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Biotin end-labeled or unlabeled oligonucleotides and other
chemicals were from Sigma Chemical Co.
Cell Culture
The human cell line HeLa (cervical cancer, ATCC CCL-2) was
maintained in DMEM with 10% FBS. EA.hy926 cells (ATCC
CRL-2922), which were derived from fusion of HUVEC with
A549 cells (lung adenocarcinoma epithelial cell line, ATCC CCL-
185), were cultured in DMEM that contained 10% FBS and HAT
media supplement. EA.hy926 cells were a gift from Dr. Cora
Edgell at the University of North Carolina.
Plasmid constructs
The reporter constructs for the exon 1a promoter and the
various exon 1a mutants were prepared by PCR with 21983/
+266-luc [10] as the template. Digested PCR products were
inserted into pGL3-basic vector and verified by sequencing. The
expression vectors for NF-Y subunits, YY1, dominant-negative
mutant YY1S339/S342 and USF1/2 were all previously described
[22,45,46,47]. The expression constructs p300 and CBP were
purchased from Addgene (MA).
Transient transfection and luciferase assays
Cells were seeded in 24-well plates and grown to ,70%
confluence. On the following day, the cells were co-transfected
with 0.1 to 0.5 mg of reporter plasmid, 5 ng of Renilla plasmid
pRL-CMV, 0.3 to 0.9 mg of plasmids expressing the genes of
interest or empty vector plasmid to compensate for the amount of
DNA. Fugene HD reagent (Roche, IN) was used for the delivery of
plasmids into cells. At 24 h after transfection, cell lysates for
measurement of firefly and Renilla luciferase activities were
prepared using Passive Lysis Buffer (Promega) according to the
manufacturer’s directions.
Electrophoresis mobility shift assays (EMSA)
For in vitro binding reactions, 2 ml of nuclear extract were
incubated with the biotin end-labeled probes at room temperature
for 20 minutes in 10 mM Tris pH 7.5, 50 mM KCl, 50 mM
NaCl, 1 mM DTT, 0.5 mM EDTA, 5% glycerol, 0.1% NP-40,
5 mM MgCl2, 1 mg/ml BSA, and 50 ng/ml poly dI-dC. For
competition or super-shift experiments, the nuclear extracts were
treated with excessive amounts of unlabeled probes or 4 mg
antibody for 30 minutes at room temperature prior to the addition
of the biotin end-labeled probes. The reaction mixes were then
loaded onto 4.5% polyacrylamide gel electrophoresis (PAGE) and
run at 100 V in 0.56 TBE buffer for 1.5 hours following the
detection according to the manufacturer’s directions.
Co-immunoprecipitation and Western blotting
For co-immunoprecipitation assays, 1610
7 HeLa cells were
collected, washed in cold-PBS, suspended in 1.5 ml cold lysis
buffer, and incubated on ice for 30 min with occasional mixing.
The cell lysate was centrifuged at 10,000 g for 10 min at 4uCt o
pellet cellular debris. The supernatant was treated with 2 mgo f
antibody and 20 ml of protein G plus-agarose beads (Santa Cruz,
CA) for overnight incubation. The bead-antibody pellets were
washed with lysis buffer containing 0.5 M NaCl, suspended in
16SDS loading buffer and boiled for 5 min. Proteins were
subjected to polyacrylamide gel electrophoresis on 7.5% poly-
acrylamide gels and were then electro-transferred to polyvinyli-
dene difluoride membranes. Membranes were blocked with 5%
non-fat dry milk for 1 h at room temperature and then incubated
for 2 h at room temperature with primary antibodies. After
washing, the membranes were incubated at room temperature for
2 hours with a 1:10,000 dilution of a horseradish peroxidase-
conjugated secondary antibody (Sigma) and detection was carried
out with ECL (Amersham, UK).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay (ChIP) assays were
performed via a commercially chromatin immunoprecipitation
kit (Cell Signaling, MA), using antibodies against either YY1, NF-
YA, USF1/2 or p300. Briefly, cell contents were first cross-linked
by adding formaldehyde. Cross-linked lysates were then digested
by Micrococcal nuclease. After digestion, the samples were
centrifuged and the supernatants were diluted 5-fold in ChIP
buffer. Cross-linked chromatin was incubated overnight with YY1,
NF-YA, USF1/2, p300 antibody or normal rabbit IgG at 4uC.
Antibody-protein-DNA complexes were isolated by immunopre-
cipitation with 30 ml of protein G magnetic beads. After extensive
washing, pellets were eluted and formaldehyde cross-linking was
reversed by 2-h incubation at 65uC after addition of proteinase K
and NaCl. Samples were purified and used as a template for PCR.
ChIP primers 5-GTT CCA CTT TCA CCC ACG TGA GC-3
and 5-GAG AAG ATG AAT GGC CCT GCT CCA-3 were used
to amplify a 119-base pair fragment corresponding to the core
exon 1a promoter.
Lentivirus packaging and knockdown
shRNA sequences were selected according to published criteria
[48]: YY1i-AACCTGAAATCTCACATCTTA [49], NFYAi-
GCCCTTTACTACAGGACAGAA (Sigma), and TurboGFPi
control-CGTGATCTTCACCGACAAGAT (Sigma). Oligos cod-
ing for the shRNAs were designed and cloned into the lentiviral
vector pLKO.1 [50].
For lentivirus packaging, 50–60% confluent HEK293T cells
(ATCC CRL-11268) were transfected using Fugene HD reagent
(Roche) with a mixture of 10 mg of pLKO.1 shRNA plasmid,
7.5 mg of envelope encoding pMD2.G plasmid, and 2.5 mg of the
packaging vector psPAX2 plasmid (Addgene). The culture
supernatant containing the packaged virus was harvested 48 h
after transfection and titered p24 concentration (ng/ml) by ELISA.
A general guideline is 1 ng p24=10
5 Transducing Units (TU)
[51]. Transduction of EA.hy926 cells was performed with
recombinant pLKO.1 lentivirus in the presence of 8 mg/ml
polybrene as transduction enhancer. Cells were continuously
cultured for 4 days before shRNA-mediated knockdown experi-
ments were performed.
RNA isolation and RT-PCR
Total RNA was isolated using TRIZOL reagent (GIBCO,
Grand Island, NY), and 2 mg was reverse-transcribed using iScript
cDNA synthesis kit (Bio-Rad, Carlsbad, CA). Amplification was
performed using Advantage 2 PCR kit (Clontech, Mountain View,
CA). The PCR products were separated on 1% agarose gels. The
parameters and primers for SVCT2 exon 1a were described
previously [6].
SVCT2 Exon 1a Promoter Regulation
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Statistical significance was determined by analysis of variance
with post-hoc testing using the software program Sigma Stat 2.0
(Jandel Scientific, San Rafael, CA). Significance was based on a P
value of ,0.05.
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